According to an analysis of follow-up data from 436 patients with autoimmune myasthenia gravis (MG) and 102 with chronic inflammatory demyelinating polyradiculoneuritis (CIDP), receiving intravenous immunoglobulin (IVIg) as maintenance therapy:
- is associated with a reduction in the incidence of cancers occurring at least one year after diagnosis.
- this decrease correlates with the duration of IVIg treatment
- it is significant for CIDP (10% vs 26%), as well as for myasthenia gravis once its moderate forms treated with pyridostigmine alone are excluded (16% vs 28.8%).
These results confirm those of previous preclinical studies (in mice) and case reports of patients with cancer receiving IVIg.
